V. De Sanctis et al., Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine, J PED END M, 11, 1998, pp. 827-833
An auxological and endocrinological study was performed in 21 thalassaemic
patients with growth retardation and skeletal dysplasia secondary to desfer
rioxamine. Bone metaphyseal proximal tibial or iliac crest biopsy was perfo
rmed in six. patients with severe genu valgum or non-traumatic vertebral co
mpression. GH insufficiency/deficiency (GH deficiency: peak after stimulati
on test below 6 ng/ml) was found in 72% of our thalassaemic patients with s
keletal dysplasia, but in only 41% of patients without skeletal dysplasia,
Bone histology showed abnormal chondrocytes, alteration of staining pattern
of cartilage, irregular columnar cartilage and lacunae in the cartilaginou
s tissue. The behaviour of bone tissue was unpredictable (presence of thick
or thin osteoid layer), Bone microfractures were sometimes present. The bo
ne microstructure showed scarce mineralization, which was evenly or irregul
arly distributed. The bone tissue apatitic phase was quantitatively reduced
. The hardness of bone tissue was remarkably lower than that of normal bone
in three out of six patients. In conclusion, iron chelation therapy in pat
ients with acquired skeletal dysplasia seems to interfere with GH secretion
. The early identification of clinical and radiological abnormalities of sk
eletal dysplasia is of paramount importance in preventing severe bone destr
uction.